Biotheranotics

Biotheranotics, Inc. is a commercial-stage molecular diagnostics company dedicated to developing and providing diagnostic, prognostic, and predictive tests to support physicians in treating cancer patients. The company is located in San Diego, California, and offers testing services through its CLIA-certified, CAP-accredited laboratory, which is directly licensed or otherwise authorized to conduct testing in all 50 states. Biotheranostics is a leader in developing evidence-based biomarkers to address unmet medical needs and has laid the groundwork for rapid growth. Biotheranostics has commercialized two proprietary, highly differentiated products targeting breast cancer and all metastatic cancers: the Breast Cancer Index (BCI) and CancerTYPE ID (CTID). Both the Breast Cancer Index and CancerTYPE ID have received Medicare coverage through the Palmetto MolDx* program and are supported by a robust IP portfolio. Recent milestones for the Breast Cancer Index growth platform include Medicare coverage in November 2014 and positive reception at the San Antonio Breast Cancer Symposium in early December 2014.